05:53 AM EDT, 06/23/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Saturday its oral GLP-1, orforglipron, met the primary endpoint in a phase 3 trial in adults with type 2 diabetes, delivering statistically significant reductions in A1C levels and body weight versus placebo.

Orforglipron reduced A1C by an average 1.3% to 1.6% and body weight by up to 7.9% across tested doses, in the 40-week ACHIEVE-1 study.

The highest dose group saw an average weight loss of 16 lbs.

In key secondary endpoints, the therapy also led to a higher proportion of patients achieving the American Diabetes Association target of A1C under 7%, with up to 76.2% of patients reaching the goal, compared to 28% with placebo.

Discontinuation due to adverse events was under 8% across all dose groups, Lilly said.

The company remains on track to submit orforglipron for weight management this year and for type 2 diabetes in 2026.

Later this year, Lilly expects to share topline results from ACHIEVE-2, evaluating orforglipron compared with dapagliflozin, and ACHIEVE-3, evaluating orforglipron compared to oral semaglutide.